![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 173-179, April 2003
-Opioid Receptors Inhibits Pruritus Evoked by
Subcutaneous or Intrathecal Administration of Morphine in Monkeys
Departments of Anesthesiology (N.N.N.) and Pharmacology (M.C.H.K.,
H.L., M.S.S., J.H.W.), Medical School, Division of Medicinal Chemistry,
College of Pharmacy (K.S., H.I.M.), University of Michigan, Ann Arbor,
Michigan; and Department of Pharmacology (S.K.), Wakayama Medical
University, Wakayama, Japan
Pruritus (itch sensation) is the most common side effect associated
with spinal administration of morphine given to humans for
analgesia. A variety of agents have been proposed as
antipruritics with poorly understood mechanisms and they are effective
with variable success.
-Opioid agonists possess several actions that are opposite to µ-opioid agonists. We proposed to investigate the
role of
-opioid receptors (KORs) in morphine-induced scratching and
antinociception in monkeys. Scratching responses were
counted by observers blinded to treatment. Antinociception was measured by a warm water (50°C) tail-withdrawal assay. Pretreatment with low
doses of
trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]-cyclohexyl)-benzeneacetamide (U-50488H) (0.032-0.18 mg/kg s.c.), a selective KOR agonist, dose dependently suppressed the s.c. morphine dose-effect curve for scratching and potentiated s.c. morphine-induced
antinociception. In addition, s.c. U-50488H attenuated i.t. morphine
(10 and 32 µg)-induced scratching while maintaining or enhancing i.t.
morphine-induced antinociception. The combination of s.c. or i.t.
morphine with low doses of U-50488H did not cause sedation. More
importantly, pretreatment with 3.2 mg/kg nor-binaltorphimine, a
selective KOR antagonist, blocked the effects of s.c. U-50488H on both
s.c. and i.t. morphine-induced scratching. These results indicate that activation of KOR attenuates morphine-induced scratching without interfering with antinociception in monkeys. This mechanism-based finding provides functional evidence in support of the clinical potential of KOR agonists as antipruritics in the presence of MOR
agonist-induced pruritus.
This article has been cited by other articles:
![]() |
E. R. Butelman, M. Mandau, K. Tidgewell, T. E. Prisinzano, V. Yuferov, and M. J. Kreek Effects of Salvinorin A, a {kappa}-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High {kappa}-Receptor Homology to Humans J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nakatsuka, S. C. Minogue, J. Lim, C. J. Montgomery, C. A. Court, S. Malherbe, Y. Csanyi-Fritz, R. A. Kearney, L. Phillips, K. Reid, et al. Intravenous nalbuphine 50 {micro}g{middle dot}kg-1 is ineffective for opioid-induced pruritus in pediatrics: [La nalbuphine intraveineuse a 50 {micro}g{middle dot}kg-1 est inefficace contre le prurit induit par les opioides chez des enfants]. Can J Anesth, November 1, 2006; 53(11): 1103 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wikstrom, R. Gellert, S. D. Ladefoged, Y. Danda, M. Akai, K. Ide, M. Ogasawara, Y. Kawashima, K. Ueno, A. Mori, et al. {kappa}-Opioid System in Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Studies J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3742 - 3747. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, K. Tang, S. Inan, D. Siebert, U. Holzgrabe, D. Y.W. Lee, P. Huang, J.-G. Li, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Three Distinct {kappa} Ligands (Salvinorin A, TRK-820 and 3FLB) on {kappa} Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 220 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. H. Ko, M. S. Song, T. Edwards, H. Lee, and N. N. Naughton The Role of Central {micro} Opioid Receptors in Opioid-Induced Itch in Primates J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 169 - 176. [Abstract] [Full Text] [PDF] |
||||